Eloralintide: amylin selectivity enters Phase 3
Eloralintide (LY3841136) is Eli Lilly’s selective long-acting amylin receptor agonist—an amylin-pathway candidate that is not a GLP-1 and not a unimolecular GLP/amylin dual like amycretin. Phase 2 obesity data published in The Lancet showed dose-dependent weekly weight loss from roughly 9% to 20% at 48 weeks versus near-zero placebo change. Phase 3 monotherapy and combination programs (including with tirzepatide) are now the operational story. This profile is for researchers tracking the post-incretin pipeline.
Mechanism: AMY1R-preferring amylin agonism
Amylin is co-secreted with insulin and reduces energy intake via central and gastrointestinal satiety pathways. Eloralintide is engineered as a selective agonist with substantially higher potency at human AMY1R than at the calcitonin receptor, and it uses fatty-acid albumin binding to support once-weekly dosing. That selectivity story is why it is grouped with cagrilintide-class thinking rather than with pure GLP-1s.
Phase 2 weight-loss results
In NCT06230523, adults with obesity/overweight without T2D received weekly placebo or eloralintide at 1, 3, 6, or 9 mg, or escalation arms to 9 mg, for 48 weeks. Efficacy-estimand mean body-weight changes spanned about −9% (1 mg) to about −20% (9 mg and 6–9 mg) versus about −0.4% placebo. GI events were the dominant tolerability theme.
Phase 3 and combinations
Multiple Phase 3 trials are registered for obesity with and without T2D, osteoarthritis pain, OSA, and incretin combination settings. Sponsor disclosures on EloraTZP (eloralintide + tirzepatide) describe large mid-stage weight-loss increments over tirzepatide alone—still investigational.
How it differs from CagriSema and amycretin
CagriSema co-formulates cagrilintide (amylin) with semaglutide (GLP-1). Amycretin is a single molecule hitting GLP-1 and amylin together. Eloralintide is selective amylin agonism that can be stacked or combined strategically with incretins rather than baking GLP-1 into the same chain. Pipeline literacy starts with that taxonomy.
Regulatory status
Not FDA-approved. Not a compounded 503A bulk-substance story like the HHS six. Treat research vials and trial drug as distinct from approved obesity pharmacotherapy.
On Peptide Hub
Database and dosing-guide entries now include an eloralintide SKU framed on published trial dose bands. Pair this article with CagriSema and amycretin materials when comparing amylin-pathway options.
Editorial Note: This article is published for research and educational purposes only. Peptide Hub does not sell peptides, receive commissions from peptide vendors, or endorse any specific supplier. All compounds discussed are research peptides not approved for human therapeutic use except where specifically noted. This is not medical advice.
Sources
- Lancet 2025 eloralintide Phase 2 (doi:10.1016/S0140-6736(25)02155-5)
- ClinicalTrials.gov NCT06230523, NCT07321886
- CagriSema guide